Quick Answer
Taysha Gene Therapies, Inc. reported Stockholders Equity of $246.94 million for fiscal year 2025.
Taysha Gene Therapies, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $246.94M | +245.2% |
| 2024 | $71.53M | -4.6% |
| 2023 | $74.94M | +7796.4% |
| 2022 | $949.0K | -99.0% |
| 2021 | $95.38M | -62.0% |
| 2020 | $251.30M | +186249.6% |
| 2019 | -$135.0K | — |
| 2019 | $0.00 | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $218.99M | +146.6% | -12.0% |
| June 30, 2025 | $248.73M | +128.5% | +351.7% |
| March 31, 2025 | $55.06M | +2.2% | -23.0% |
| December 31, 2024 | $71.53M | -4.6% | -19.5% |
| September 30, 2024 | $88.80M | +280.8% | -18.4% |
| June 30, 2024 | $108.87M | +393.3% | +102.2% |
| March 31, 2024 | $53.85M | +460.2% | -28.1% |
| December 31, 2023 | $74.94M | +7796.4% | +252.6% |
- Taysha Gene Therapies, Inc. showed an increase of +245.2% in Stockholders Equity compared to the prior fiscal year.
- The most recent figure is from Taysha Gene Therapies, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: